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Background: Sorafenib (Sb) is a multiple kinase inhibitor targeting both tumour cell proliferation and angiogenesis that may
further act as a potent radiosensitizer by arresting cells in the most radiosensitive cell cycle phase. This phase I open-label,
noncontrolled dose escalation study was performed to determine the safety and maximum tolerated dose (MTD) of Sb in
combination with radiation therapy (RT) and temozolomide (TMZ) in 17 patients with newly diagnosed high-grade glioma.
Methods: Patients were treated with RT (60Gy in 2Gy fractions) combined with TMZ 75mgm 2 daily, and Sb administered at
three dose levels (200mg daily, 200mg BID, and 400mg BID) starting on day 8 of RT. Thirty days after the end of RT, patients
received monthly TMZ (150–200mgm 2 D1–5/28) and Sb (400mg BID). Pharmacokinetic (PK) analyses were performed on day 8
(TMZ) and on day 21 (TMZ&Sb) (Clinicaltrials ID: NCT00884416).
Results: The MTD of Sb was established at 200mg BID. Dose-limiting toxicities included thrombocytopenia (two patients),
diarrhoea (one patient) and hypercholesterolaemia (one patient). Sb administration did not affect the mean area under the curve(0–24)
and mean Cmax of TMZ and its metabolite 5-amino-imidazole-4-carboxamide (AIC). Tmax of both TMZ and AIC was delayed from
0.75 (TMZ alone) to 1.5 h (combined TMZ/Sb). The median progression-free survival was 7.9 months (95% confidence interval (CI):
5.4–14.55), and the median overall survival was 17.8 months (95% CI: 14.7–25.6).
Conclusions: Although Sb can be combined with RT and TMZ, significant side effects and moderate outcome results do not
support further clinical development in malignant gliomas. The robust PK data of the TMZ/Sb combination could be useful in
other cancer settings.
Most patients with glioblastoma (GBM) are currently treated with
maximal safe resection followed by concomitant radiation therapy
(RT) and temozolomide (TMZ) followed by adjuvant TMZ (Stupp
et al, 2005). Despite some long-term benefit obtained in a small
fraction of patients with this combined treatment, the median
overall survival remains poor, at 14 months only (Stupp et al,
2005). Strategies to improve this outcome are desperately needed.
One attractive option is to explore the potential of drugs targeting
intracellular pathways involved in gliomagenesis.
Sorafenib (Sb) (Nexavar) was initially developed as a specific
inhibitor of the serine/threonine Raf kinase (Wilhelm et al, 2004)
and has been approved by the US Food and Drug Administration
for the treatment of patients with kidney cancer and hepatocellular
carcinoma (Kane et al, 2006; Llovet et al, 2008). Further in vitro
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and in vivo studies showed that Sb targets multiple kinases,
including vascular endothelial growth factor receptor-2 (VEGFR),
VEGFR-3, Flt3, c-RAF, wild type and V599E mutant B-Raf,
platelet-derived growth factor receptor b (PDGFRb), c-KIT,
fibroblast growth factor receptor 1, p38a and RET (Liu et al,
2006). Thus, the cellular consequences of Sb are diverse
(promotion of apoptosis, inhibition of tumour cell proliferation
and angiogenesis, etc.), possibly leading to tumour growth arrest by
targeting both tumour cells and blood vessels.
In the case of malignant glioma, several pathways in tumour and
endothelial cells have key roles in disease progression and
resistance to treatment. High levels of vascular endothelial growth
factor (VEGF) and VEGF receptors are frequently observed
(Salmaggi et al, 2003), PDGFR is often activated (Hermanson
et al, 1992; Shih et al, 2004; Martinho et al, 2009), and up to 30% of
patients carry an amplicon on chromosome 4q12 comprising the
VEGFR2, PDGFR-a and KIT genes (Joensuu et al, 2005; Puputti
et al, 2006; Holtkamp et al, 2007). In addition, although mutations
in Ras or Raf are rare, the MAPK pathway is frequently activated,
leading to poor prognosis (Davies et al, 2002). Altogether, several
kinases involved in glioma progression are potentially targeted by
Sb, which therefore appears as a very attractive drug candidate to
be tested.
The synergistic mode of action of the association of Sb not only
with TMZ but also with RT is supported by experimental and
clinical observations: combined with or following RT, Sb was
shown to induce cell cycle arrest and a reduction in colony-
forming units, as well as a delay in tumour growth in vivo in
animal models (Plastaras et al, 2007). More recent data confirmed
that Sb, TMZ and RT synergistically reduced the tumour cell
viability (Den et al, 2012), suggesting that the optimal benefit of
this drug may be reached by combining it with RT (Dal Lago et al,
2008). Here we report the results of a phase I study of Sb combined
with TMZ and RT in the upfront management of malignant
glioma.
MATERIALS AND METHODS
Patient selection. Patients with newly diagnosed high-grade
glioma (WHO grade III or GBM) for whom treatment with RT
and TMZ was considered medically reasonable were eligible for
inclusion in this study. Eligibility criteria further included ageX18
years, ECOG performance status 0–2 and a life expectancy of at
least 3 months. Patients were also required to have adequate renal,
hepatic, cardiac and bone marrow function and to be on stable or
decreasing dose of steroids in the 2 weeks prior to enrolment. All
patients with reproductive potential were required to use effective
birth control. Patients on stable anticoagulation therapy were
allowed to enter the study. Given the primary aim of this phase I
study, O6-methylguanine DNA-methyltransferase gene (MGMT)
determination was performed in all patients but was not used as
the selection or stratification criterion.
Exclusion criteria included having previous or current malig-
nancies at other sites (with the exception of cervical carcinoma
in situ, non melanoma carcinoma of the skin, superficial bladder
tumour (Ta, Tis and T1) or any cancer curatively treated43 years
prior to study entry), serious medical or psychiatric illness that
might interfere with the prescribed treatment, history of HIV
infection, chronic hepatitis C or B, having had organ allograft,
renal dialysis, as well as prior exposure to Ras pathway inhibitors.
Of note, in our institution, all brain tumour patients are treated
exclusively with non-enzyme-inducing anti-seizure medication.
This investigator-driven study was developed and written at the
Geneva University Hospitals. All patients provided written
informed consent in accordance with institutional guidelines.
Approval was obtained from the Institutional Review Board
of the University Hospitals of Geneva and the study was conducted
in accordance with Good Clinical Practice Guidelines and the
Declaration of Helsinki. The trial was registered as NCT00884416
on clinicaltrials.gov.
Study design. The study was a classical 3þ 3 design, phase I,
single-arm, single-centre study conducted to establish the max-
imum tolerated dose (MTD) of Sb in conjunction with TMZ and
concurrent RT in patients with newly diagnosed high-grade
gliomas (Le Tourneau et al, 2009). A minimum of three patients
were included at each dose level. If none of the patients
experienced a dose-limiting toxicity (DLT) until the end of week
10 (completion of RT and a 4 week break period), the next dose
level was opened. If one patient had a DLT, three additional
patients were enrolled at that dose level. If no additional patients
had a DLT until the end of week 10, then the dose level was
increased. If one or more of the additional patients had a DLT
(therefore two or more out of six patients), then that dose level was
deemed to be too toxic and an additional three patients were
accrued to the prior dose level if only three patients had been
enrolled. If well tolerated, this dose level would be documented as
being the MTD.
Study outcomes. The primary objectives of this study were to
determine the safety profile and tolerability of Sb when
administered in conjunction with TMZ and RT and to establish
the MTD of this combination. Secondary objectives were to
evaluate pharmacokinetics (PKs), tumour response and survival.
Treatment plan and dosing levels. The phase I part of the study
was defined as the period of concurrent treatment with RT, TMZ
and Sb as well as the following 4-week period, where patients were
off treatment. The maintenance phase was defined as the period
covering the six cycles of maintenance TMZ and Sb. As concurrent
administration of Sb and TMZ without RT had previously been
described in patients with melanoma (Amaravadi et al, 2009), this
treatment phase was not considered to be a part of the phase I
study and Sb was administered at a fixed level of 400mg twice daily
(BID).
Radiation therapy consisted of a conventionally fractionated
regimen to a total dose of 60Gy, administered in 30 daily fractions
of 2Gy, with or without volumetric modulated arc therapy. Target
volume definition was based on pre- and postoperative MRI with
mandatory coregistration (fusion) of the MRI scan and the
planning CT. Radiation therapy was delivered in accordance with
Radiation Therapy Oncology Group guidelines and dose con-
straints. Standard dose constraints were used for normal structures.
All patients were required to start treatment within 6 weeks of
surgery. Temozolomide was administered continuously at a dose of
75mgm 2 concurrently with RT, starting on the first day of RT,
and administered daily for up to 42 days or until the end of RT.
Three dose levels for Sb were planned as follows: cohort 1
received a single daily oral dose of 200mg, cohort 2 received
200mg Sb BID and cohort 3 received 400mg BID. In the
concurrent phase, Sb was started at the pre-specified dose level on
day 8 after the start of RT and TMZ.
After a break of 4 weeks, patients were treated in the
maintenance phase with TMZ (150mgm 2 on d1–5 for the first
cycle of 28 days) followed for a total of up to six cycles of TMZ
given at 200mgm 2 on d1–5/28 if the first cycle was tolerated
without significant side effects. Sorafenib was restarted on day 1 of
the first cycle at 400mg BID regardless of the dose level in the
concurrent phase. Treatment was continued until evidence of
progressive disease or excessive toxicity, patient’s refusal to
continue or if the treating physician felt termination to be in the
patient’s best interest.
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Safety. All patients who received at least one dose of Sb were
evaluated for safety. Patients were evaluated continuously through-
out the study for physical assessment, vital signs and incidence of
adverse events, DLTs and abnormal laboratory values.
Toxicities were graded according to the National Cancer
Institute’s Common Terminology Criteria for Adverse Events,
version 3.0. The DLTs for this study were defined as any of the
following adverse events related to the combination treatment:
grade 4 thrombocytopenia, grade 4 neutropenia lasting over 7 days,
grade 3 or 4 febrile neutropenia, or any grade 3 or 4 non-
haematologic toxicities except alopecia, nausea, vomiting, hypo-
phosphataemia, fatigue or fever that can be rapidly controlled by
adequate measures.
Pharmacokinetics. Pharmacokinetic profiles of TMZ were deter-
mined on day 7 (prior to the initiation of Sb) and day 21 (after 14
days of treatment with Sb) of the concurrent treatment. On these
days, plasma samples were collected prior to the ingestion of TMZ
and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 h thereafter to
determine the concentrations of TMZ and of its metabolite
5-amino-imidazole-4-carboxamide (AIC). For the determination
of TMZ and AIC, blood samples (5ml aliquots) were collected into
a tube containing ammonium heparin, and centrifuged at 2000 g
for 5min at þ 4 1C to separate the plasma. Two ml of the plasma
was then transferred to polypropylene tubes containing 0.2ml of
1 M hydrochloric acid, mixed for 1min and frozen (at  70 1C or
lower) until assayed. Samples were kept in the dark and on ice at all
times during manipulations. Temozolomide and AIC were
quantified in plasma samples by liquid chromatography–mass
spectrometry (LC-MS/MS). The lower limit of quantification
(LOQ) was 5 mg l 1 for TMZ and 10mg l 1 for AIC. Assays were
performed at Bayer HealthCare, Berlin, Germany.
Plasma concentrations of Sb were also determined on day 21
prior to administration of Sb, as well as 0.5, 1, 2, 4, 8, 10 and 12 h
thereafter. Blood samples were centrifuged at 2000 g for 10min
at þ 4 1C and the plasma was then transferred to a polypropylene
tube and frozen at  20 1C until analysis. The determination of
plasma concentrations of Sb was performed using a fully validated
specific LC-MS/MS assay method with a LOQ of 0.01mg l 1 for
Sb. Assays were performed at Bayer HealthCare.
Pharmacokinetic parameters were derived by non-compart-
mental analysis, using WinNonlin v.4.1a. Primary PK parameters
were Cmax and area under the curve (AUC)(0–12) for Sb, and Cmax
and AUC(0–24) for TMZ. Secondary PK parameters assessed
included Tmax and T1/2. Data are presented as arithmetic
mean±s.d., except for Tmax, for which median and range are
presented. Ratios of day 21 to day 7 PK parameters and 90%
confidence interval (CI) were derived from geometric means.
MGMT promoter methylation status determination. The pro-
moter methylation status of the MGMT was assessed on DNA
isolated from paraffin-embedded tumour samples obtained at initial
surgery. MDxHealth, Lie`ge, Belgium, performed the test with
quantitative methylation-specific PCR (Vlassenbroeck et al, 2008).
Efficacy. All patients who received at least one dose of RT and
TMZ were assessed for tumour response based on MacDonald
criteria. Time to treatment failure, event-free survival and overall
survival were also assessed. Tumour measurements were per-
formed at baseline, 4 weeks after completion of Sb/TMZ/RT
treatment and every 2 months thereafter.
RESULTS
A total of 17 patients were enrolled from April 2009 to March 2011
in this dose escalation study: six in cohort 1, six in cohort 2 and
three in cohort 3; two patients signed consent but had to be
excluded because of neurological deterioration prior to start of
treatment. The baseline demographics for all patients are shown in
Table 1. All patients were diagnosed with GBM except one patient
of cohort 2 (WHO grade III anaplastic oligoastrocytoma after
pathological review). Seven patients had a complete or near-
complete (over 90%) resection, five patients had an incomplete
resection (o90%) and three patients (all in cohort 2) underwent
Table 1. Patient baseline characteristics
Patient Sex
Age at
diagnosis Diagnosis
Type of
resection
MGMT
Status
ECOG
at inclusion
Sorafenib adminstration in
phase I part
Dose level 1 1 DLT
Patient 1 M 67.1 GBM Incomplete Unmethylated 0 DLT (thrombocytopenia grade 4)
Patient 2 M 37.3 GBM Complete Invalid test 0 Completed
Patient 3 F 62.4 GBM Near complete Unmethylated 0 Completed
Patient 4 F 64.0 GBM Incomplete Unmethylated 0 Completed (pulmonary embolism, grade 4)
Patient 5: screening failure
Patient 6 M 43.3 GBM Complete Unmethylated 0 Completed
Patient 7 M 54.6 GBM Incomplete Unmethylated 0 Completed
Dose level 2 1 DLT
Patient 8: screening failure
Patient 9 F 61.7 GBM Near complete Methylated 0 Completed
Patient 10 F 48.5 GBM Incomplete Methylated 0 Completed
Patient 11 M 62.5 GBM Biopsy Invalid test 1 Completed
Patient 15 F 25.1 GBM Complete Unmethylated 0 Completed
Patient 16 F 57.8 GBM Biopsy Not determined 0 Completed
Patient 17 F 45.3 OA grade 3 Biopsy Not determined 0 DLT (thrombocytopenia grade 4)
Dose level 3 2 DLTs
Patient 12 F 41.2 GBM Near complete Unmethylated 0 Interrupted (pt’s wish after hand-foot syndrome
grade 3)
Patient 13 F 47.8 GBM Incomplete Methylated 1 DLT (hypercholesterolaemia and
triglyceridaemia, grade 3)
Patient 14 F 69.9 GBM Complete Unmethylated 0 DLT (diarrhoea grade 4)
Abbreviations: DLT¼dose-limiting toxicity; ECOG¼Eastern Cooperative Oncology Group performance status; GBM¼glioblastoma; MGMT¼O6-methylguanine DNA-methyltransferase
gene; OA¼oligoastrocytoma.
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biopsy only. All but two patients presented with an ECOG of 0. Of
note, given the risk of interaction with Sb and TMZ, none of the
patients included in this study were treated with enzyme-inducing
antiepileptic agents.
Adverse events and dose-limiting toxicities. The 17 patients
enrolled in the study were evaluable for safety analyses (Table 2).
All patients (100%) experienced at least one treatment-related
adverse event at any grade. Eleven patients (65%) reported
treatment-related adverse events of grade 3 or 4. The most
common toxicities were haematologic, fatigue and hand-foot skin
reaction (HFSR). Hand-foot skin reaction was reported more
frequently with higher doses of Sb (cohorts 2 and 3). A total of four
patients developed DLTs: two cases of grade 4 thrombocytopenia
(one in cohort 1 and one in cohort 2), one grade 3 hypercholester-
olaemia and hypertriglyceridaemia, and one grade 3 diarrhoea
(both in cohort 3). These toxicities failed to improve within the
preset time frame and were evaluated to be definitely or probably
linked to the combination of Sb with TMZ and/or RT. Thus, the
recommended dose for Sb in conjunction with RT and daily TMZ
(75mgm 2 per day) was established at 200mg BID. Of note, all
patients who did not develop DLTs completed the Sb and TMZ
treatment of the concomitant phase of the protocol.
During the maintenance phase, 7 out of 17 patients did not
restart Sb: 4 patients had developed DLTs during the initial phase,
2 patients withdrew their consent to participate to the maintenance
phase of the trial, mainly because of non-DLT adverse reactions
experienced during the initial phase, and 1 patient was taken off
study because of tumour progression on the MRI performed
4 weeks after completion of concomitant RT/TMZ/Sb. Four
additional patients prematurely stopped the Sb and TMZ
treatments due to adverse events (grade 3 HFSR, grade 4
neutropenia, grade 4 liver enzyme abnormalities and grade 3
hypertriglyceridaemia, and grade 4 thrombocytopenia).
Pharmacokinetic studies. Pharmacokinetic parameters were
assessed in all 12 patients of cohorts 1 and 2 and in two patients
of cohort 3. Analysis of PKs for Sb was performed on day 21 of the
combined treatment (RT/TMZ/Sb). Mean AUC(0–12) (mg h l
 1)
was 23.0±10.5, 40.9±25.2 and 63.8±4.3, and mean Cmax was
3.1±1.8, 6.3±4.8 and 7.24±0.05, for cohorts 1, 2 and 3,
respectively. The concentration of Sb in plasma remained stable
over at least 12 h.
Regarding TMZ, comparison of PK parameters from day 7
(TMZ in the absence of Sb) and day 21 (TMZ plus Sb) showed that
Sb administration at any of the studied doses had no effect on both
mean AUC(0–24) and mean Cmax of TMZ and its metabolite AIC
(Figure 1a and b and Table 3). The narrow ranges of all values
confirm the limited inter-individual variability of bioavailability
when both drugs are taken together. Temozolomide half-life was
also unaffected by Sb, averaging 1.6–1.7 h for all cohorts with or
without Sb. AIC half-life was also unaffected by Sb (Table 3). The
only PK parameter that was slightly affected was TMZ Tmax, which
was slightly prolonged from 0.75 to 1.5 h with combined Sb/TMZ
at the MTD in cohort 2 compared with TMZ alone (Table 3).
Response to treatment. The best responses observed in this study
were 2 partial responses (cohorts 1 and 2, 13.3%) and 10 stable
diseases (four in cohort 1, three in cohort 2 and three in cohort 3,
66.6%). Of note, 2 of these 10 patients maintained complete
responses following complete resection (one patient in cohorts 1
and 2, each). One patient of cohort 1 and two patients of cohort 2
showed progressive disease (20% of all patients).
Of note, seven patients (46% of all patients) presented with
pseudoprogression on the first MRI performed 4 weeks after
completion of RT. For this study, pseudoprogression was defined
as a radiological progression of the lesion in the first MRI
performed after completion of RT with a subsequent MRI that
showed either stable disease (six patients in our study) or partial
remission (one patient). The median progression-free survival (PFS)
Table 2. Adverse events observed during concomitant phase
Toxicity
Grade
1–2,
n(%)
Grade
3, n(%)
Grade
4, n(%)
Grade
5, n(%)
Haematological-Thrombocytopenia 1 (6.6%) 3 (20%) 2 (13.3%) 0
Haematological-Lymphopenia 0 1 (6.6%) 2 (13.3%) 0
Haematological-Neutropenia 1 (6.6%) 1 (6.6%) 1 (6.6%) 0
Pulmonary embolism 0 0 1 (6.6%) 0
Cutaneous-Skin rash 6 (40%) 0 0 0
Cutaneous-Hand-foot syndrome 4 (26.6%) 2 (13.2 %) 0 0
Dyslipidemia 1 (6.6%) 1 (6.6%) 0 0
Diarrhoea 1 (6.6%) 1 (6.6%) 0 0
Constipation 0 1 (6.6%) 0 0
Hypertension 2 (13.3%) 2 (13.3%) 0 0
Heart rate abnormalities 4 (26.6%) 1 (6.6%) 0 0
Fatigue 3 (20%) 2 (13.3%) 0 0
% are expressed as number of events compared with the entire cohort of patients.
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Figure 1. (A) Plasma concentrations of TMZ following multiple doses
of 75mgm 2 of TMZ without (Day 7, Cycle 1) and after concomitant
treatment (Day 21, Cycle 1) with multiple oral doses of 200mg BID
sorafenib in patients of cohort 2 (geometric means, geometric SD;
n¼ 6). (B) Plasma concentrations of AIC following multiple doses
of 75mgm 2 of TMZ without (Day 7, Cycle 1) and after concomitant
treatment (Day 21, Cycle 1) with multiple oral doses of 200mg
BID sorafenib in patients of cohort 2 (geometric means, geometric
SD; n¼ 6).
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was 7.9 months (95% CI: 5.4–14.55) and the 6-month PFS was
86.7%. Of the 13 patients who developed progressive disease,
5 (38%) did not receive any further treatment, mainly because of
high kinetics of tumour growth and poor performance status. Five
patients (38%) received a single additional line of treatment (single
bevacizumab in four patients, re-resection followed by bevacizumab:
one patient). Of those patients, one is still on treatment. One patient
was treated with two further lines of treatment (dose-dense TMZ
followed by bevacizumab) and two patients have received three
further lines of treatment (dose-dense TMZ/bevacizumab/CCNU
and bevacizumab/CCNU/metronomic TMZ, respectively). Of note,
2 patients out of 17 (12%) developed impressive leptomeningeal
dissemination of the GBM (confirmed by CSF cytology) following
treatment of recurrent disease with bevacizumab (Figure 2). The
median overall survival was 17.8 months (95% CI: 14.7–25.6).
DISCUSSION
When combined with RT and continuous administration of TMZ
(75mgm 2 per day), the MTD of Sb was established at 200mg
twice daily in this study. The main toxicity was grade 3/4
thrombocytopenia, with an increased incidence in our study,
compared with what has been reported for TMZ or Sb alone
(43.3% vs 19% and o2%, respectively (Andenmatten et al, 2013)).
In contrast, the incidences of neutropenia, lymphopenia, skin rash or
hand-foot skin reaction were similar to those reported with either
TMZ or Sb alone (Stupp et al, 2005; Escudier et al, 2007; Llovet et al,
2008). Other toxicities leading to the MTD were intractable
diarrhoea, as well as grade 3 hypertriglyceridaemia and hyper-
cholesterolaemia. Whether the risk of this last toxicity, which is a
rare side effect observed with TMZ (investigator’s brochure), is
increased by the combined administration of Sb and TMZ is
unknown.
Another trial also investigated the combination of Sb with initial
RT or re-irradiation in conjunction with TMZ in patients with
de novo or recurrent gliomas (Den et al, 2012). The MTD for Sb was
also suggested to be 200mg twice daily, concurring with our data.
However, this study had important limitations because of a complex
design leading to various RT durations and doses, and the inclusion
of patients in different settings. Consequently, the majority of
patients were exposed to minimal amounts of Sb. Indeed, over 60%
of patients discontinued treatment prior to the end of radiotherapy.
Moreover, the doses of RT considerably varied (35Gy stereotactic vs
60Gy in 30 fractions) and the treatment period extended between
2–6 weeks, further shortening the exposition to the combination
treatment, with the risk of missing potential toxicities that may arise
following prolonged exposure to the therapeutic agents. In contrast,
in our study, over 78% of the total planned doses of Sb have been
administered during the concomitant phase, definitively establishing
the Sb MTD at 200mg twice daily.
Another finding from our study is that the addition of Sb did
not significantly change the plasma concentrations of TMZ. Thus,
there is no pharmacological impediment to combining Sb, TMZ
and irradiation. However, it is interesting to note that at the dose
level of 200mg Sb BID, Tmax was delayed by B0.75 h when TMZ
and Sb were co-administered. This effect was not observed at the
dose of 200mg per day, potentially because the concentration of Sb
was too small to induce this interaction. At the dose of 400mg Sb
BID, two patients only were evaluated, complicating the inter-
pretation of the results from cohort 3. This delay in Tmax may
however be clinically relevant, as TMZ is routinely administered
1 h before irradiation so that the peak plasma TMZ concentration
coincides with the administration of RT.
Although this study was not powered to determine the effects on
PFS or radiographic response rate, the results observed in this
phase I study suggest that addition of Sb to RT and TMZ does not
result in significant improvement of PFS, when compared with the
Table 3. Pharmacokinetic parameters of TMZ and its metabolite AIC after administration of TMZ 75mgm2 per day without (day 7) and with varying
doses of Sb (day 21)
Cohort 1, n¼6 Cohort 2, n¼6 Cohort 3, n¼2
TMZ AIC TMZ AIC TMZ AIC
Cmax (mg l
1), mean±s.d.
TMZ alone (day 7) 6.1±1.7 0.37±0.08 4.1±0.9 0.33±0.09 4.4±1.6 0.40±0.09
TMZ & Sb (day 21) 6.7±3.1 0.32±0.08 3.9±1.2 0.31±0.15 3.6±1.4 0.21±0.25
Ratio (day 21/day 7) 1.02 0.87 0.94 0.76 0.8 0.31
90% CI 0.80–1.31 0.79–0.96 0.71–1.26 0.38–1.50 0.71–0.91 0.001–1.88
AUC(0–24)(mgh l1), mean±s.d.
TMZ alone (day 7) 11.7±1.9 1.58±0.48 10.8±1.4 1.64±0.31 10.5±0.5 1.70±0.45
TMZ & Sb (day 21) 13.3±2.42 1.70±0.47 11.9±0.96 1.51±0.79 10.3±1.89 n.d.
Ratio (day 21/day 7) 1.14 1.08 1.1 0.73 0.97 n.d.
90% CI 1.04–1.24 1.00–1.18 0.97–1.25 0.35–1.52 0.52–1.81
Tmax(h), median (range)
TMZ alone (day 7) 0.25 (0.25–1.50) 1.75 (1.50–2.00) 0.75 (0.25–1.50) 1.75 (1.50–4.00) 0.63 (0.50–0.75) 2.00 (2.00–2.00)
TMZ & Sb (day 21) 0.50 (0.25–2.00) 2.00 (0.75–3.00) 1.50 (0.25–2.00) 2.00 (1.50–3.00) 0.88 (0.75–1.00) 2.00 (2.00–2.00)
T1/2 (h), mean±s.d.
TMZ alone (day 7) 1.59±0.09 1.71±0.21 1.69±0.08 2.37±0.92 1.78±0.19 2.09±0.26
TMZ & Sb (day 21) 1.71±0.07 1.99±0.11 1.77±0.16 2.56±1.48 1.65±0.02 2.29±0.45
Abbreviations: AUC¼ area under the curve; Cmax¼ concentration max; n.d¼ not done; Sb¼ sorafenib; Tmax¼ time max; TMZ¼ temozolomide.
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phase III landmark trial (7.9 vs 6.9 months) (Stupp et al, 2005).
There are some potential reasons for these disappointing results.
Although the plasma levels of both TMZ and Sb were within the
expected range (Lee et al, 2012), CNS distribution studies have
shown that CNS penetration of Sb is limited, predominantly by the
breast cancer resistance protein (ABCG2/BRCP), a member of the
ATP-binding cassette transporters (Agarwal et al, 2011). Such
properties may also contribute to the disappointing results
obtained in other studies combining Sb and TMZ without
irradiation for patients with recurrent GBM or as standalone
maintenance treatment following RT (Hainsworth et al, 2010;
Reardon et al, 2011; Lee et al, 2012). Moreover, the addition of
TMZ to RT has been shown to favour the induction of an
exaggerated reaction to RT, which has been termed pseudo-
progression (Taal et al, 2008).
Interestingly, in our cohort, the median overall survival of 17.8
months was unexpectedly longer than the OS observed in the
landmark EORTC trial (14.2 months) and in a recent phase II trial
that evaluated the role of bevacizumab and everolimus in addition
to RT and TMZ as upfront treatment for GBM (13.9 months)
(Hainsworth et al, 2012). Our results are, however, in line with a
number of phase II trials evaluating the upfront addition of
bevacizumab to RT and TMZ, which have reported a median OS of
19.6, 21.3 and 23 months (Lai et al, 2011; Vredenburgh et al, 2012).
Whether this moderate rise in overall survival may be partially
related to the addition of Sb, reflects the overall improvement
observed with the current multidisciplinary management of
patients with high-grade gliomas or is an unexpected patient
selection bias (especially given the better overall performance
status of the patients enrolled in this study) cannot be determined
without a phase III study. However, the minimal response rates
along with the disappointing PFS results obtained in the present
study did not support this further step of clinical development.
Also of concern was the impressive leptomeningeal dissemina-
tion observed in two patients following salvage treatment with
bevacizumab. It remains unclear whether this observation is
related to Sb, but this possibility cannot be excluded with certainty.
Inhibition of VEGF signalling has been shown to lead to a
pro-invasive phenotype in mouse GBM models and in a subset of
GBM patients treated with bevacizumab (Lu et al, 2012). Given the
extended VEGF inhibition through Sb and bevacizumab, one may
hypothesise that activation of alternative pathways may select for
more aggressive and invasive tumour phenotypes.
In conclusion, the PK results of this study definitely show that
TMZ and Sb can be combined without major pharmacological
interaction. However, the importance of side effects and the rather
poor outcome results obtained in patients with newly diagnosed
high-grade glioma do not support the further clinical exploration
of this combined modality (RT/TMZ/Sb).
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